Head to head
CagriSema against Cagrilintide
The combination against its other half. Cagrilintide alone had a 302 person arm in the same phase 3 that tested the combination, which is the cleanest way to ask what the amylin analogue does on its own and what it only does alongside semaglutide.
Column A
CagriSemaCagriSema (cagrilintide + semaglutide)
A fixed combination of the amylin analogue cagrilintide and semaglutide that produced about 23% weight loss in Phase 3 and has been filed for FDA approval.
Column B
CagrilintideCagrilintide (long-acting amylin receptor agonist)
An investigational once-weekly amylin agonist studied with semaglutide (CagriSema) for powerful combined weight loss.
Side by side, on the facts we can check
| Attribute | CagriSema | Cagrilintide |
|---|---|---|
| Category | Metabolic | Metabolic |
| FDA status | Investigational; NDA submitted to the FDA in December 2025 (REDEFINE 1 and 2); decision expected 2026 | Investigational, not FDA-approved |
| Half-life | ~7 days (weekly dosing) | ~7 days |
| Molecular weight | Mixture; cagrilintide 4,409 Da plus semaglutide 4,113.6 Da | ~3,700 Da |
| Mechanism | Simultaneously agonizes amylin receptors (satiety) and the GLP-1 receptor (appetite, insulin, gastric emptying) for additive weight loss. | Agonizes amylin receptors in the hypothalamus and brainstem to promote satiety and delay gastric emptying, complementing GLP-1 signaling. |
| Human studies cited | 3 | 3 |
| Legal status, US | Investigational, not approved | Investigational, not approved |
Frequently asked questions
What is the difference between CagriSema and Cagrilintide?
CagriSema: A fixed combination of the amylin analogue cagrilintide and semaglutide that produced about 23% weight loss in Phase 3 and has been filed for FDA approval. Cagrilintide: An investigational once-weekly amylin agonist studied with semaglutide (CagriSema) for powerful combined weight loss.
Which has stronger research evidence, CagriSema or Cagrilintide?
This database does not grade compounds. It counts what was run in people: 3 of the 3 studies cited on the CagriSema profile were human work, against 3 of 3 for Cagrilintide. Those counts are of our own citation lists and understate any larger literature, and neither is a recommendation.
Are CagriSema and Cagrilintide FDA-approved?
CagriSema: Investigational; NDA submitted to the FDA in December 2025 (REDEFINE 1 and 2); decision expected 2026. Cagrilintide: Investigational, not FDA-approved.
Related posts
Blog articles that cover CagriSema or Cagrilintide, newest first.
- Dispatch / Sep 12, 2026 / 8 minDispatch 001: Five Retatrutide Phase 3 Trials Have Finished And None Has Posted Results
- Metabolic / Sep 8, 2026 / 9 minMariTide (Maridebart Cafraglutide): The Once-Monthly GLP-1 Agonist and GIP Blocker, Explained
- Metabolic / Sep 8, 2026 / 9 minCagrilintide: The Amylin Half of CagriSema, and Why People Search 'Cagrilintide with Retatrutide'
- Metabolic / Sep 8, 2026 / 9 minRetatrutide vs Tirzepatide vs Semaglutide vs the Pill: The 2026 GLP-1 Field Guide
Reviewed Sep 2026. This page sets two published records side by side. It is educational, it is not medical advice, and it contains no dosing protocols or recommendations for personal use.